Maxidex For Suspension
NDC Package 82667-600-05

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Maxidex (dexamethasone) for suspensions is a medication used to treat certain eye conditions due to inflammation or injury. This formulation utilizes a for suspension delivery system. Marketed by Harrow Eye, Llc, this product is identified by NDC 82667-600 and is authorized under FDA application NDA013422.

Identification & Billing

NDC Package Code
82667-600-05
Package Description
1 BOTTLE, PLASTIC in 1 CARTON / 5 mL in 1 BOTTLE, PLASTIC
Product Code
82667-600
11-Digit Billing Format
82667060005
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Maxidex
Non-Proprietary Name
Dexamethasone
Substance Name
Dexamethasone
Dosage Form
For Suspension - A product, usually a solid, intended for suspension prior to administration.
Administration Route
Ophthalmic - Administration to the external eye.
Active Ingredient(s)
DEXAMETHASONE 1 mg/mL
Pharmacologic Class
Usage Information
This medication is used to treat certain eye conditions due to inflammation or injury. Dexamethasone works by relieving symptoms such as swelling, redness, and itching. It belongs to a class of drugs known as corticosteroids. This medication may also be used to treat swelling, redness, and itching of the outer ear due to inflammatory conditions.

Regulatory & Marketing

Labeler Name
Harrow Eye, Llc
Product Type
Human Prescription Drug
FDA Application #
NDA013422
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
04-07-2025
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 82667-600-05 identifies a specific commercial package of 1 bottle, plastic in 1 carton / 5 ml in 1 bottle, plastic of Maxidex, a human prescription drug labeled by Harrow Eye, Llc. This for suspension is formulated for ophthalmic use and contains dexamethasone as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Harrow Eye, Llc on April 07, 2025. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

This medication is used to treat certain eye conditions due to inflammation or injury. Dexamethasone works by relieving symptoms such as swelling, redness, and itching. It belongs to a class of drugs known as corticosteroids. This medication may also be used to treat swelling, redness, and itching of the outer ear due to inflammatory conditions.

How is this Harrow Eye, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 82667060005. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
82667-600-05
11-Digit CMS (5-4-2)
82667-0600-05

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.